Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Information from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma
  1. Home
  2. Publications
  3. Supplementary Information from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

Supplementary Information from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

Authors:
  • JLJinwen Liu
    Jinwen Liu
  • GHGaowei Huang
    Gaowei Huang
  • HLHao Lin
    Hao Lin
  • RYRui Yang
    Rui Yang
  • WZWenhao Zhan
    Wenhao Zhan
  • CLCheng Luo
    Cheng Luo
  • YWYukun Wu
    Yukun Wu
  • LCLingwu Chen
    Lingwu Chen
  • XMXiaopeng Mao
    Xiaopeng Mao
  • JCJunxing Chen
    Junxing Chen
  • BHBin Huang
    Bin Huang

Open Access
Publisher website
Google Scholar
  • 14 March 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/0008-5472.28595162
Abstract
Figure S1-S17,Table S1-S2,Supplementary methods
Keywords
  • BIOLOGICAL AGENTS & THERAPIES
  • CELL-BASED THERAPEUTICS
  • DRUG RESISTANCE
  • CLINICAL DRUG RESISTANCE
  • NON-TRANSPORTER-BASED DRUG RESISTANCE
  • NOVEL MECHANISMS
  • GENITOURINARY CANCERS
  • RENAL CANCER
  • METABOLISM
  • METABOLIC PATHWAYS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.